DOCSLIB.ORG

USING RNA-SEQ to CHARACTERIZE the BIOLOGICAL BASIS of VARIATION in FEED EFFICIENCY in BROILER CHICKENS by Nan Zhou a Thesis Su

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
USING RNA-SEQ to CHARACTERIZE the BIOLOGICAL BASIS of VARIATION in FEED EFFICIENCY in BROILER CHICKENS by Nan Zhou a Thesis Su USING RNA-SEQ TO CHARACTERIZE THE BIOLOGICAL BASIS OF VARIATION IN FEED EFFICIENCY IN BROILER CHICKENS by Nan Zhou A thesis submitted to the Faculty of the University of Delaware in partial fulfillment of the requirements for the degree of Master of Science in Animal Science Spring 2015 © 2015 Nan Zhou All Rights Reserved ProQuest Number: 1596914 All rights reserved INFORMATION TO ALL USERS The quality of this reproduction is dependent upon the quality of the copy submitted. In the unlikely event that the author did not send a complete manuscript and there are missing pages, these will be noted. Also, if material had to be removed, a note will indicate the deletion. ProQuest 1596914 Published by ProQuest LLC (2015). Copyright of the Dissertation is held by the Author. All rights reserved. This work is protected against unauthorized copying under Title 17, United States Code Microform Edition © ProQuest LLC. ProQuest LLC. 789 East Eisenhower Parkway P.O. Box 1346 Ann Arbor, MI 48106 - 1346 USING RNA-SEQ TO CHARACTERIZE THE BIOLOGICAL BASIS OF VARIATION IN FEED EFFICIENCY IN BROILER CHICKENS by Nan Zhou Approved: __________________________________________________________ Behnam Abasht, Ph.D. Professor in charge of thesis on behalf of the Advisory Committee Approved: __________________________________________________________ Limin Kung, Jr., Ph.D. Chair of the Department of Animal and Food Sciences Approved: __________________________________________________________ Mark W. Rieger, Ph.D. Dean of the College of Agriculture and Natural Resources Approved: __________________________________________________________ James G. Richards, Ph.D. Vice Provost for Graduate and Professional Education ACKNOWLEDGMENTS The work was partly funded by Delaware Bioscience Center for Advanced Technology and Heritage Breeders, LLC. Thank to my collaborators, Behnam Abasht and William R Lee, for their great contributions on this work. The work can’t be completed without you. I would like to thank my committee members for their support. First, I want to thank Behnam Abasht for providing me many good opportunities and teaching me so many things. You brought me to the U.S. and gave me a very warm “home” for the last two and a half years. You made me to be a better person. Thank you to Larry Cogburn, Walter Bottje and William R Lee for serving on my thesis committee and helping me throughout my degree. Your support has been greatly appreciated over the last two years. Thank you to my lab mates, Zhu Zhuo, Marie Mutryn and Weixuan Fu, for helping me with my study and live. Thank you all my friends for helping me and making me not alone during the last two and a half years. I want to give a special thank to my parents for their support and unconditional love. You are always my greatest treasure. iii TABLE OF CONTENTS LIST OF TABLES ....................................................................................................... vii LIST OF FIGURES ..................................................................................................... viii ABSTRACT .................................................................................................................. ix Chapter 1 BACKGROUND ................................................................................................ 1 1.1 The Definition of Feed Efficiency ............................................................ 1 1.2 The Significance of Improving Feed Efficiency ....................................... 2 1.3 Factors Affecting Feed Efficiency in Chickens ........................................ 3 1.3.1 External Factors ............................................................................ 3 1.3.2 Internal Factors .............................................................................. 4 1.4 Previous Studies in Chicken Feed Efficiency ........................................... 5 1.4.1 Mitochondrial Function and Feed Efficiency ............................... 5 1.4.2 Global Gene Expression Study of Feed Efficiency ....................... 7 1.5 Introduction to RNA-seq Technique ......................................................... 8 1.6 Introduction to Skeletal Muscle .............................................................. 10 1.6.1 Skeletal Muscle Metabolism ....................................................... 10 1.6.2 Skeletal Muscle Fiber Types ....................................................... 11 1.7 Adverse Effects of Intense Genetic Selection ......................................... 12 1.8 Project Introduction ................................................................................. 13 REFERENCES ................................................................................................. 15 2 MESSENGER RNA SEQUENCING AND PATHWAY ANALYSIS PROVIDE NOVEL INSIGHTS INTO THE BIOLOGICAL BASIS OF CHICKENS’ FEED EFFICIENCY ................................................................. 20 2.1 Background ............................................................................................. 20 2.2 Methods ................................................................................................... 22 iv 2.2.1 Animals and Sample Collection .................................................. 22 2.2.2 RNA Isolation ............................................................................. 23 2.2.3 RNA-seq Library Preparation and Sequencing ........................... 24 2.2.4 Mapping Reads to the Chicken Reference Genome ................... 24 2.2.5 Differential Expression Analysis ................................................ 25 2.2.6 Nanostring nCounter® Gene Expression Assay ......................... 25 2.2.7 Ingenuity Pathway Analysis ........................................................ 26 2.3 Results and Discussion ............................................................................ 26 2.3.1 Phenotype Measurements ............................................................ 26 2.3.2 Transcriptional Profile of Chicken Breast Muscle ...................... 27 2.3.3 Gene Differential Expression Analysis ....................................... 29 2.3.4 Confirmation of RNA-seq Data .................................................. 31 2.3.5 Overview of IPA Analysis .......................................................... 33 2.3.6 Increased Muscle Growth and Remodeling in High-FE Chickens. ..................................................................................... 37 2.3.7 Growth Hormone (GH) and IGFs/PI3K/AKT Signaling Pathway Over-represented in the Differentially Expressed Genes….. ..................................................................................... 43 2.3.8 Inflammatory Response in the Breast Muscle of High-FE Broilers… .................................................................................... 48 2.3.9 Free Radical Scavenging Enriched in the Differentially Expressed Genes between High- and Low-FE Broilers .............. 52 2.3.10 Transcriptional Regulation of Hypoxia-inducible Factor-1α (HIF1α).. ...................................................................................... 58 2.4 Conclusions ............................................................................................. 61 REFERENCES ................................................................................................. 64 3 CHARACTERIZATION OF METABOLIC DIFFERENCES IN THE BREAST MUSCLE OF HIGH AND LOW FEED EFFICIENCY CHICKENS USING RNA-SEQ ...................................................................... 79 3.1 Introduction ............................................................................................. 79 3.2 Methods ................................................................................................... 81 3.2.1 Animals and RNA-seq Analysis ................................................. 81 3.2.2 Ingenuity Pathway Analysis ........................................................ 82 3.2.3 Ultimate pH (pHu) Measurement and Analysis .......................... 82 3.2.4 Determination of Breast Muscle Glycogen Content ................... 83 3.2.5 Quantitative Reverse Transcription-PCR (qRT-PCR) ................ 83 v 3.3 Results and Discussion ............................................................................ 85 3.3.1 Carbohydrate Metabolism ........................................................... 85 3.3.1.1 Glycerol-3-Phosphate Shuttle ...................................... 89 3.3.1.2 Transcriptional Control of Carbohydrate Metabolism . 92 3.3.2 Glycogen Depletion in Breast Muscle of the HFE Chickens ...... 93 3.3.3 Transcriptional Regulation of Lipid Metabolism ........................ 96 3.3.3.1 Cholesterol Biosynthesis and Reverse Cholesterol Transport… .................................................................. 97 3.3.3.2 Lipid Catabolism .......................................................... 99 3.3.3.3 Lipogenesis ................................................................ 101 3.3.4 Amino Acid Metabolism ........................................................... 102 3.3.4.1 The Regulation of Amino Acid Metabolism .............. 103 3.3.4.2 Glutamine Metabolism ............................................... 106 3.3.5 Metabolism and Inflammatory Response .................................. 107 3.3.5.1 Effects of Inflammatory Response on Metabolic Regulation.. ................................................................ 107 3.3.5.2 Lipid-derived Inflammatory Mediators ...................... 108 3.4 Conclusions ..........................................................................................
Load more

Recommended publications
  • The Attenuated Secretion of Hyaluronan by UVA
    International Journal of Molecular Sciences Article The Attenuated Secretion of Hyaluronan by UVA-Exposed Human Fibroblasts Is Associated with Up- and Downregulation of HYBID and HAS2 Expression via Activated and Inactivated Signaling of the p38/ATF2 and JAK2/STAT3 Cascades Shuko Terazawa 1,†, Mariko Takada 1,†, Yoriko Sato 1, Hiroaki Nakajima 2 and Genji Imokawa 1,* 1 Center for Bioscience Research & Education, Utsunomiya University, Tochigi 321-8505, Japan; [email protected] (S.T.); [email protected] (M.T.); [email protected] (Y.S.) 2 School of Bioscience and Biotechnology, Tokyo University of Technology, Tokyo 192-0982, Japan; [email protected] * Correspondence: [email protected]; Tel.: +81-28-649-5282 † These authors contributed equally to this work. Abstract: Little is known about the effects on hyaluronan (HA) metabolism of UVA radiation. This study demonstrates that the secretion of HA by human dermal fibroblasts (HDFs) is down- Citation: Terazawa, S.; Takada, M.; regulated by UVA, accompanied by the down- and upregulation of mRNA and protein levels of Sato, Y.; Nakajima, H.; Imokawa, G. the HA-synthesizing enzyme (HAS2) and the HA-degrading protein, HYaluronan Binding protein The Attenuated Secretion of Involved in HA Depolymerization(HYBID), respectively. Signaling analysis revealed that the ex- Hyaluronan by UVA-Exposed posure distinctly elicits activation of the p38/MSK1/CREB/c-Fos/AP-1 axis, the JNK/c-Jun axis, Human Fibroblasts Is Associated and the p38/ATF-2 axis, but downregulates the phosphorylation of NF-kB and JAK/STAT3. A signal with Up- and Downregulation of inhibition study demonstrated that the inhibition of p38 significantly abrogates the UVA-accentuated HYBID and HAS2 Expression via mRNA level of HYBID.
    [Show full text]
  • Anti-MYOZ2 (GW22350F)
    3050 Spruce Street, Saint Louis, MO 63103 USA Tel: (800) 521-8956 (314) 771-5765 Fax: (800) 325-5052 (314) 771-5757 email: [email protected] Product Information Anti-MYOZ2 antibody produced in chicken, affinity isolated antibody Catalog Number GW22350F Formerly listed as GenWay Catalog Number 15-288-22350F, Myozenin-2 Antibody. – Storage Temperature Store at 20 °C The product is a clear, colorless solution in phosphate buffered saline, pH 7.2, containing 0.02% sodium azide. Synonyms: Myozenin 2, Calsarcin-1; FATZ-related protein 2 Species Reactivity: Human Product Description Myozenins may serve as intracellular binding proteins Tested Applications: WB involved in linking Z-disk proteins such as alpha-actinin. Recommended Dilutions: Recommended starting dilution gamma-filamin. TCAP/telethonin. LDB3/ZASP and localizing for Western blot analysis is 1:500, for tissue or cell staining calcineurin signaling to the sarcomere. Plays an important 1:200. role in the modulation of calcineurin signaling. May play a role in myofibrillogenesis. Note: Optimal concentrations and conditions for each application should be determined by the user. NCBI Accession number: NP_057683.1 Swiss Prot Accession number: Q9NPC6 Precautions and Disclaimer This product is for R&D use only, not for drug, household, or Gene Information: Human .. MYOZ2 (51778) other uses. Due to the sodium azide content a material Immunogen: Recombinant protein Myozenin 2 safety data sheet (MSDS) for this product has been sent to the attention of the safety officer of your institution. Please Immunogen Sequence: GI # 7706595, sequence 1 - 264 consult the Material Safety Data Sheet for information regarding hazards and safe handling practices.
    [Show full text]
  • Mutations in MYOZ1 As Well As MYOZ2 Encoding the Calsarcins Are Not Associated with Idiopathic and Familial Dilated Cardiomyopathy
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by MDC Repository Repository of the Max Delbrück Center for Molecular Medicine (MDC) Berlin (Germany) http://edoc.mdc-berlin.de/8815/ Mutations in MYOZ1 as well as MYOZ2 encoding the calsarcins are not associated with idiopathic and familial dilated cardiomyopathy Maximilian G. Posch, Andreas Perrot, Rainer Dietz, Cemil Özcelik, Sabine Pankuweit, Volker Ruppert, Anette Richter, and Bernhard Maisch Published in final edited form as: Molecular Genetics and Metabolism. 2007 Jun; 91(2): 207-208 doi: 10.1016/j.ymgme.2007.02.014 Elsevier (The Netherlands) ► Letter to the editor Mutations in MYOZ1 as well as MYOZ2 encoding the calsarcins are not associated with idiopathic and familial dilated cardiomyopathy Maximilian G. Posch, Andreas Perrot, Rainer Dietz, Cemil Özcelik, Sabine Pankuweit, Volker Ruppert, Anette Richter, and Bernhard Maisch 1 Charité – Universitätsmedizin Berlin/Cardiology at Campus Buch & Virchow Klinikum, Helios-Kliniken and Max- Delbrück Center for Molecular Medicine, Wiltbergstrasse 50, 13125 Berlin, Germany 2 Department of Internal Medicine and Cardiology, Philipps University Marburg, Baldingerstrasse, 35043 Marburg, Germany a very weak mRNA expression of MYOZ1 [5]. Conversely, Dear Editor, MYOZ2 encoding calsarcin-1 is predominantly expressed We have read the article of Arola and colleagues [1] with in cardiomyocytes and to lesser extends in skeletal great interest. The authors report a candidate gene muscle [5,6]. Calsarcin-1 is located at the sarcomeric Z- approach in the MYOZ1 gene encoding calsarcin-2 in 185 disk and interacts with DCM disease genes like telethonin patients with idiopathic dilated cardiomyopathy (iDCM).
    [Show full text]
  • HAS2-AS1 Is a Novel LH/Hcg Target Gene Regulating HAS2 Expression and Enhancing Cumulus Cells Migration Yuval Yung *† , Libby Ophir†, Gil M
    Yung et al. Journal of Ovarian Research (2019) 12:21 https://doi.org/10.1186/s13048-019-0495-3 RESEARCH Open Access HAS2-AS1 is a novel LH/hCG target gene regulating HAS2 expression and enhancing cumulus cells migration Yuval Yung *† , Libby Ophir†, Gil M. Yerushalmi, Micha Baum, Ariel Hourvitz† and Ettie Maman† Abstract Background: The cumulus expansion process is one of the LH mediated ovulatory processes. Hyaluronan synthase 2 (HAS2) regulates the synthesis of hyaluronic acid, the main component of the cumulus expansion process. Recently, the lncRNA HAS2 antisense RNA 1 (HAS2-AS1) was identified in our global transcriptome RNA-sequencing of novel ovulation associated genes. The role of HAS2-AS1 in HAS2 regulation w.as studied previously with contradictive results in different models but not in the ovary. Taken together the induction of HAS2-AS1 and the important role of HAS2 in the cumulus expansion process, we hypothesize that HAS2-AS1 regulate HAS2 expression and function in the ovary. Therefore we undertook to study the expression, regulation, and possible functional role of HAS2-AS1 in the human ovary. Results: HAS2-AS1, located within the HAS2 gene that was highly regulated in our library. We found that HAS2-AS1 express mainly in cumulus cells (CCs). Furthermore, HAS2-AS1 showed low expression in immature CCs and a significant increase expression in mature CCs. Functional studies reveal that inhibition of HAS2-AS1 by siRNA caused decrease expression of HAS2. Furthermore, inhibition of HAS2-AS1 by siRNA results in decrease migration of granulosa cells. Conclusions: Our results suggest that HAS2-AS1 is an LH/hCG target gene that plays a positive role in HAS2 expression and thus might play a role in regulating cumulus expansion and migration.
    [Show full text]
  • Resveratrol Inhibits Cell Cycle Progression by Targeting Aurora Kinase a and Polo-Like Kinase 1 in Breast Cancer Cells
    3696 ONCOLOGY REPORTS 35: 3696-3704, 2016 Resveratrol inhibits cell cycle progression by targeting Aurora kinase A and Polo-like kinase 1 in breast cancer cells RUBICELI MEDINA-AGUILAR1, LAURENCE A. Marchat2, ELENA ARECHAGA OCAMPO3, Patricio GARIGLIO1, JAIME GARCÍA MENA1, NICOLÁS VILLEGAS SEPÚlveda4, MACARIO MartÍNEZ CASTILLO4 and CÉSAR LÓPEZ-CAMARILLO5 1Department of Genetics and Molecular Biology, CINVESTAV-IPN, Mexico D.F.; 2Molecular Biomedicine Program and Biotechnology Network, National School of Medicine and Homeopathy, National Polytechnic Institute, Mexico D.F.; 3Natural Sciences Department, Metropolitan Autonomous University, Mexico D.F.; 4Department of Molecular Biomedicine, CINVESTAV-IPN, Mexico D.F.; 5Oncogenomics and Cancer Proteomics Laboratory, Universidad Autónoma de la Ciudad de México, Mexico D.F., Mexico Received December 4, 2015; Accepted January 8, 2016 DOI: 10.3892/or.2016.4728 Abstract. The Aurora protein kinase (AURKA) and the MDA-MB-231 and MCF-7 cells. By western blot assays, we Polo-like kinase-1 (PLK1) activate the cell cycle, and they confirmed that resveratrol suppressed AURKA, CCND1 and are considered promising druggable targets in cancer CCNB1 at 24 and 48 h. In summary, we showed for the first time therapy. However, resistance to chemotherapy and to specific that resveratrol regulates cell cycle progression by targeting small-molecule inhibitors is common in cancer patients; thus AURKA and PLK1. Our findings highlight the potential use of alternative therapeutic approaches are needed to overcome resveratrol as an adjuvant therapy for breast cancer. clinical resistance. Here, we showed that the dietary compound resveratrol suppressed the cell cycle by targeting AURKA Introduction and PLK1 kinases. First, we identified genes modulated by resveratrol using a genome-wide analysis of gene expression Cancer development results from the interaction between in MDA-MB-231 breast cancer cells.
    [Show full text]
  • Discovery and Systematic Characterization of Risk Variants and Genes For
    medRxiv preprint doi: https://doi.org/10.1101/2021.05.24.21257377; this version posted June 2, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license . 1 Discovery and systematic characterization of risk variants and genes for 2 coronary artery disease in over a million participants 3 4 Krishna G Aragam1,2,3,4*, Tao Jiang5*, Anuj Goel6,7*, Stavroula Kanoni8*, Brooke N Wolford9*, 5 Elle M Weeks4, Minxian Wang3,4, George Hindy10, Wei Zhou4,11,12,9, Christopher Grace6,7, 6 Carolina Roselli3, Nicholas A Marston13, Frederick K Kamanu13, Ida Surakka14, Loreto Muñoz 7 Venegas15,16, Paul Sherliker17, Satoshi Koyama18, Kazuyoshi Ishigaki19, Bjørn O Åsvold20,21,22, 8 Michael R Brown23, Ben Brumpton20,21, Paul S de Vries23, Olga Giannakopoulou8, Panagiota 9 Giardoglou24, Daniel F Gudbjartsson25,26, Ulrich Güldener27, Syed M. Ijlal Haider15, Anna 10 Helgadottir25, Maysson Ibrahim28, Adnan Kastrati27,29, Thorsten Kessler27,29, Ling Li27, Lijiang 11 Ma30,31, Thomas Meitinger32,33,29, Sören Mucha15, Matthias Munz15, Federico Murgia28, Jonas B 12 Nielsen34,20, Markus M Nöthen35, Shichao Pang27, Tobias Reinberger15, Gudmar Thorleifsson25, 13 Moritz von Scheidt27,29, Jacob K Ulirsch4,11,36, EPIC-CVD Consortium, Biobank Japan, David O 14 Arnar25,37,38, Deepak S Atri39,3, Noël P Burtt4, Maria C Costanzo4, Jason Flannick40, Rajat M 15 Gupta39,3,4, Kaoru Ito18, Dong-Keun Jang4,
    [Show full text]
  • Cardiomyocyte-Specific Deletion of Orai1 Reveals Its Protective Role in Angiotensin-II-Induced Pathological Cardiac Remodeling
    cells Article Cardiomyocyte-Specific Deletion of Orai1 Reveals Its Protective Role in Angiotensin-II-Induced Pathological Cardiac Remodeling Sebastian Segin 1,2, Michael Berlin 1,2, Christin Richter 1, Rebekka Medert 1,2, Veit Flockerzi 3, Paul Worley 4, Marc Freichel 1,2 and Juan E. Camacho Londoño 1,2,* 1 Pharmakologisches Institut, Ruprecht-Karls-Universität Heidelberg, INF 366, 69120 Heidelberg, Germany; [email protected] (S.S.); [email protected] (M.B.); [email protected] (C.R.); [email protected] (R.M.); [email protected] (M.F.) 2 DZHK (German Centre for Cardiovascular Research), Partner Site Heidelberg/Mannheim, 69120 Heidelberg, Germany 3 Experimentelle und Klinische Pharmakologie und Toxikologie, Universität des Saarlandes, 66421 Homburg, Germany; [email protected] 4 The Solomon H. Snyder Department of Neuroscience, Johns Hopkins University, School of Medicine, Baltimore, MD 21205, USA; [email protected] * Correspondence: [email protected]; Tel.: +49-6221-54-86863; Fax: +49-6221-54-8644 Received: 26 March 2020; Accepted: 24 April 2020; Published: 28 April 2020 Abstract: Pathological cardiac remodeling correlates with chronic neurohumoral stimulation and abnormal Ca2+ signaling in cardiomyocytes. Store-operated calcium entry (SOCE) has been described in adult and neonatal murine cardiomyocytes, and Orai1 proteins act as crucial ion-conducting constituents of this calcium entry pathway that can be engaged not only by passive Ca2+ store depletion but also by neurohumoral stimuli such as angiotensin-II. In this study, we, therefore, analyzed the consequences of Orai1 deletion for cardiomyocyte hypertrophy in neonatal and adult cardiomyocytes as well as for other features of pathological cardiac remodeling including cardiac contractile function in vivo.
    [Show full text]
  • Gene % HDV Positive Cells % Infection Compared to Sictrl P-Value FDR
    % HDV % infection Gene positive compared to p-value FDR Toxicity cells siCtrl A2M 9,45 63,81 0,0001 0,0002 0,11 A4GALT 17,61 118,94 0,0887 0,1607 -0,13 A4GNT 16,11 108,83 0,0939 0,1683 0,20 AACS 15,76 106,48 0,5123 0,5979 0,00 AADAC 14,41 97,34 0,5533 0,6323 -0,03 AADACL1 14,44 97,53 0,2998 0,3678 0,14 AADAT 13,36 90,26 0,1557 0,2308 0,17 AAK1 18,00 121,58 0,0007 0,0028 0,04 AANAT 12,21 82,46 0,0004 0,0012 0,09 AARS 17,17 115,94 0,0671 0,1111 -0,13 AARSD1 14,78 99,83 0,8307 0,8622 -0,09 AASDH 18,69 126,24 0,0054 0,0129 -0,04 AASDHPPT 16,84 113,73 0,2685 0,3738 -0,05 AASS 16,33 110,31 0,0531 0,0836 -0,05 AATF 18,57 125,42 0,0111 0,0254 0,07 AATK 14,80 99,98 0,6699 0,7166 0,18 ABAT 16,31 110,16 0,0725 0,1215 0,34 ABCA1 14,86 100,36 0,9669 0,9774 0,18 ABCA10 13,09 88,44 0,3205 0,4130 0,09 ABCA12 17,44 117,81 < 0.0001 < 0.0001 -0,03 ABCA13 14,77 99,76 0,9409 0,9609 -0,04 ABCA2 10,93 73,82 0,0001 0,0003 0,19 ABCA3 10,03 67,74 0,0913 0,1645 0,23 ABCA4 12,89 87,10 0,2968 0,3890 -0,08 ABCA5 17,00 114,80 0,0598 0,1252 0,04 ABCA6 15,58 105,20 0,2367 0,3178 0,13 ABCA7 11,40 77,03 < 0.0001 < 0.0001 0,35 ABCA8 15,88 107,30 0,0001 0,0005 0,06 ABCA9 11,86 80,11 < 0.0001 < 0.0001 0,29 ABCB1 12,79 86,41 0,2516 0,3539 0,09 ABCB10 13,81 93,28 0,4109 0,4855 0,12 ABCB11 19,08 128,88 0,0079 0,0194 0,00 ABCB4 14,67 99,12 0,9630 0,9736 0,10 ABCB5 15,34 103,59 0,4524 0,5677 -0,02 ABCB6 11,31 76,40 < 0.0001 < 0.0001 0,19 ABCB7 10,89 73,56 0,0285 0,0575 0,04 ABCB8 13,69 92,50 0,0355 0,0652 0,16 ABCB9 14,27 96,37 0,8926 0,9239 0,05 ABCC1 15,92 107,56 0,2517 0,3138
    [Show full text]
  • Genotype-Related Clinical Characteristics and Myocardial Fibrosis and Their Association with Prognosis in Hypertrophic Cardiomyopathy
    Journal of Clinical Medicine Article Genotype-Related Clinical Characteristics and Myocardial Fibrosis and Their Association with Prognosis in Hypertrophic Cardiomyopathy 1, 2, 3, 3 Hyung Yoon Kim y , Jong Eun Park y, Sang-Chol Lee * , Eun-Seok Jeon , Young Keun On 3, Sung Mok Kim 4 , Yeon Hyeon Choe 4 , Chang-Seok Ki 5, Jong-Won Kim 6 and Kye Hun Kim 1 1 Department of Cardiovascular Medicine, Chonnam National University Medical School/Hospital, Gwangju 61469, Korea; [email protected] (H.Y.K.); [email protected] (K.H.K.) 2 Department of Laboratory Medicine, Hanyang University Guri Hospital, Hanyang University College of Medicine, Guri 11923, Korea; [email protected] 3 Department of Internal Medicine, Cardiovascular Imaging Center, Heart, Vascular & Stroke Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, Korea; [email protected] (E.-S.J.); [email protected] (Y.K.O.) 4 Department of Radiology, Cardiovascular Imaging Center, Heart, Vascular & Stroke Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, Korea; [email protected] (S.M.K.); [email protected] (Y.H.C.) 5 Green Cross Genome, Yongin 16924, Korea; [email protected] 6 Department of Laboratory Medicine and Genetics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, Korea; [email protected] * Correspondence: [email protected]; Tel.: +82-2-3410-3419 These authors equally contributed to this work as co-first authors. y Received: 27 April 2020; Accepted: 27 May 2020; Published: 1 June 2020 Abstract: Background: The spectrum of genetic variants and their clinical significance of Hypertrophic cardiomyopathy (HCM) have been poorly studied in Asian patients.
    [Show full text]
  • Melatonin Enhances Chondrocytes Survival Through Hyaluronic Acid Production and Mitochondria Protection
    Melatonin Enhances Chondrocytes Survival Through Hyaluronic Acid Production and Mitochondria Protection Type Research paper Keywords melatonin, mitochondrion, hyaluronic acid, NF-κB, chondrocyte Abstract Introduction Melatonin, an indoleamine synthesized mainly in the pineal gland, plays a key role in regulating the homeostasis of bone and cartilage. Reactive oxygen species (ROS) are released during osteoarthritis (OA) and associated with cartilage degradation. Melatonin is a potent scavenger of ROS. Material and methods We used rat chondrocytes as a research objective in our study and investigated the effect of melatonin. We evaluated cell viability by MTS, cell apoptosis and mitochondrial transmembrane potential (MMP) by flow cytometry, hyaluronic acid (HA) concentrations by ELISA assay, relative gene and protein expression by RT-qPCR and WB assay, the subcellular location of nuclear factor κB (NF-κB) p65 and Rh-123 dye by immunofluorescence, oxygen consumption rate (OCR) by Seahorse equipment. Results MTS and flow cytometry assay indicated that melatonin prevented H2O2-induced cell death. Melatonin suppressed the expression of HAS1 both from mRNA and protein level in time- and dose- dependent manners. Furthermore, melatonin treatment attenuated the decrease in HA production in response to H2O2 stimulation and repressed the expression of cyclooxygenase-2 (COX-2). Melatonin significantly decreasedPreprint the nuclear volume of p65 and inhibited the expression of p50 induced by H2O2. In addition, melatonin restored the MMP and OCR of
    [Show full text]
  • PPP3CA Antibody (C-Term) Affinity Purified Rabbit Polyclonal Antibody (Pab) Catalog # Ap13757b
    10320 Camino Santa Fe, Suite G San Diego, CA 92121 Tel: 858.875.1900 Fax: 858.622.0609 PPP3CA Antibody (C-term) Affinity Purified Rabbit Polyclonal Antibody (Pab) Catalog # AP13757b Specification PPP3CA Antibody (C-term) - Product Information Application WB,E Primary Accession Q08209 Other Accession P63329, P63328, P48452, NP_001124163.1, NP_000935.1 Reactivity Human Predicted Bovine, Mouse, Rat Host Rabbit Clonality Polyclonal Isotype Rabbit Ig Calculated MW 58688 Antigen Region 438-466 PPP3CA Antibody (C-term) (Cat. #AP13757b) western blot analysis in A375 cell line lysates PPP3CA Antibody (C-term) - Additional (35ug/lane).This demonstrates the PPP3CA Information antibody detected the PPP3CA protein (arrow). Gene ID 5530 Other Names PPP3CA Antibody (C-term) - Background Serine/threonine-protein phosphatase 2B catalytic subunit alpha isoform, CAM-PRP Calcium-dependent, calmodulin-stimulated catalytic subunit, Calmodulin-dependent protein phosphatase. This subunit may have a calcineurin A subunit alpha isoform, role in the calmodulin activation of calcineurin. PPP3CA, CALNA, CNA Dephosphorylates DNM1L, HSPB1 and SSH1. Target/Specificity PPP3CA Antibody (C-term) - References This PPP3CA antibody is generated from rabbits immunized with a KLH conjugated He, Z.H., et al. Eur. J. Appl. Physiol. synthetic peptide between 438-466 amino 110(4):761-767(2010) acids from the C-terminal region of human Bailey, S.D., et al. Diabetes Care PPP3CA. 33(10):2250-2253(2010) Chiocco, M.J., et al. Subst Use Misuse Dilution 45(11):1809-1826(2010) WB~~1:1000 Yang, D., et al. Int. J. Mol. Med. 26(1):159-164(2010) Format Bollo, M., et al. PLoS ONE 5 (8), E11925 (2010) Purified polyclonal antibody supplied in PBS : with 0.09% (W/V) sodium azide.
    [Show full text]
  • MDA-MB-231 Breast Cancer Cell Viability, Motility and Matrix
    Glycoconj J DOI 10.1007/s10719-016-9735-6 ORIGINAL ARTICLE MDA-MB-231 breast cancer cell viability, motility and matrix adhesion are regulated by a complex interplay of heparan sulfate, chondroitin−/dermatan sulfate and hyaluronan biosynthesis Manuela Viola1 & Kathrin Brüggemann2 & Evgenia Karousou1 & Ilaria Caon1 & Elena Caravà1 & Davide Vigetti1 & Burkhard Greve3 & Christian Stock4,5 & Giancarlo De Luca1 & Alberto Passi1 & Martin Götte2 Received: 30 June 2016 /Revised: 23 September 2016 /Accepted: 28 September 2016 # Springer Science+Business Media New York 2016 Abstract Proteoglycans and glycosaminoglycans modulate parameters were unchanged in EXT1-silenced cells. numerous cellular processes relevant to tumour progression, Importantly, these changes were associated with a decreased including cell proliferation, cell-matrix interactions, cell mo- expression of syndecan-1, decreased signalling response to tility and invasive growth. Among the glycosaminoglycans HGF and an increase in the synthesis of hyaluronan, due to with a well-documented role in tumour progression are hepa- an upregulation of the hyaluronan synthases HAS2 and ran sulphate, chondroitin/dermatan sulphate and hyaluronic HAS3. Interestingly, EXT1-depleted cells showed a downreg- acid/hyaluronan. While the mode of biosynthesis differs for ulation of the UDP-sugar transporter SLC35D1, whereas sulphated glycosaminoglycans, which are synthesised in the SLC35D2 was downregulated in β4GalT7-depleted cells, in- ER and Golgi compartments, and hyaluronan, which is syn- dicating an intricate regulatory network that connects all gly- thesized at the plasma membrane, these polysaccharides par- cosaminoglycans synthesis. The results of our in vitro study tially compete for common substrates. In this study, we suggest that a modulation of breast cancer cell behaviour via employed a siRNA knockdown approach for heparan interference with heparan sulphate biosynthesis may result in sulphate (EXT1) and heparan/chondroitin/dermatan a compensatory upregulation of hyaluronan biosynthesis.
    [Show full text]